TY - JOUR
T1 - Making Biomarkers Relevant to Healthcare Innovation and Precision Medicine
AU - Al-Dewik, Nader I.
AU - Younes, Salma N.
AU - Essa, Musthafa Mohamed
AU - Pathak, Surajit
AU - Qoronfleh, M. Walid
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1
Y1 - 2022/1
N2 - Translational medicine, the exchange between laboratory (bench) and the clinic (bedside), is decidedly taking on a vital role. Many companies are now focusing on a translational medicinal approach as a therapeutic strategy in decision making upon realizing the expenses of drug attrition in late-stage advancement. In addition, the utility of biomarkers in clinical decision and therapy guidance seeks to improve the patient outcomes and decrease wasteful and harmful treatment. Efficient biomarkers are crucial for the advancement of diagnoses, better molecular targeted therapy, along with therapeutic advantages in a broad spectrum of various diseases. Despite recent advances in the discovery of biomarkers, the advancement route to a clinically validated biomarker remains intensely challenging, and many of the candidate biomarkers do not progress to clinical applications, thereby widening the innovation gap between research and application. The present article will focus on the clinical view of biomarkers in a reverse design, addressing how a biomarker program should appear if it is expected to create an impact on personalized medicine and patient care.
AB - Translational medicine, the exchange between laboratory (bench) and the clinic (bedside), is decidedly taking on a vital role. Many companies are now focusing on a translational medicinal approach as a therapeutic strategy in decision making upon realizing the expenses of drug attrition in late-stage advancement. In addition, the utility of biomarkers in clinical decision and therapy guidance seeks to improve the patient outcomes and decrease wasteful and harmful treatment. Efficient biomarkers are crucial for the advancement of diagnoses, better molecular targeted therapy, along with therapeutic advantages in a broad spectrum of various diseases. Despite recent advances in the discovery of biomarkers, the advancement route to a clinically validated biomarker remains intensely challenging, and many of the candidate biomarkers do not progress to clinical applications, thereby widening the innovation gap between research and application. The present article will focus on the clinical view of biomarkers in a reverse design, addressing how a biomarker program should appear if it is expected to create an impact on personalized medicine and patient care.
KW - biomarkers
KW - cancer
KW - clinical trials
KW - companion diagnostics
KW - personalized medicine
KW - precision medicine
KW - therapy
KW - translational medicine
UR - http://www.scopus.com/inward/record.url?scp=85131836777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131836777&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/64f1aa59-1e43-3f92-a561-968289d5cd83/
U2 - 10.3390/pr10061107
DO - 10.3390/pr10061107
M3 - Article
AN - SCOPUS:85131836777
SN - 2227-9717
VL - 10
JO - Processes
JF - Processes
IS - 6
M1 - 1107
ER -